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Roles for thromboxane A2 and leukotrienes in endotoxin—induced acute
renal failure. Bolus iv. administration of 100 j.g/kg of E. Co/i lipopoly-
saccharide endotoxin (LPS) to adult male Munich—Wistar rats (N = 18)
resulted in a progressive fall in RBF and GFR from 6.9 0.2 SE and I.!
0.05 mI/mm to minimal values at 50 minutes of 3.8 0.4 and 0.32
0.08 (P < 0.05), respectively, without a fall in mean arterial pressure. At
50 minutes, renal cortical generation rates of PGE2 (1075 108 pg/mg
tissue), 6 keto PGF1 (221 41 pg/mg), and TxB2 (106 12 pg/mg) were
significantly higher than those of vehicle—treated control rats (N = 10,
PGE2 = 466 107, 6 keto PGFIC, = 94 3, and TxB2 = 35 3 pg/mg),
and morphologic examination revealed normal histology with notable
absence of leukocytes and platelets. Pretreatment of a third group of
nine rats with TxA2 synthetase inhibitor UK-37.248 (dazoxiben, 10
mg/kg) selectively abolished the LPS-induced rise in TxB2 (29 3
pg/mg), but not PGE2 (837 62 pg/mg) or 6 keto PGF1, (179 5 pg/mg),
prevented the fall in RBF at 50 minutes (6.3 0.4 mI/mm), and allowed
for significant preservation of GFR (0.67 0.08 mI/mm). In addition,
antagonism of endogenously produced LTs with the putative receptor
antagonist FPL55712 (N = 10, 500 pg/kg/mm x 40 mm), while not
preventing the LPS-induced rise in TxB2 generation rate (97 pg/mg);
significantly ameliorated the fall in RBF at 50 minutes (5.9 0.5
mI/mm), whereas GFR was depressed (0.46 0.13 mI/mm), but
recovered to 0.57 0.08 mI/mm at 70 mm post-LPS (P < 0.05 vs. LPS
alone). These observations point to major roles for TxA2 and
sulfidopeptide LTs in mediating the renal functional impairment of
experimental endotoxemia.
Acute oliguric renal failure is a major cause of mortality and
morbidity during endotoxemic shock [1]. The mechanism of
endotoxin—induced renal injury is not fully understood although
roles for the alpha adrenergic system, the renin angiotensin
system, and other humoral factors have been suggested [2—5].
In man, dog, and rat, endotoxin leads to an increase in renal
vascular resistance (RVR) and a decrease in glomerular filtra-
tion rate (GFR) [1—51.
Endotoxin is a potent stimulus of white blood cells in vitro
leading to activation of phospholipase A2 and release of arachi-
clonic acid [6], resulting in the synthesis of potent vasoconstric-
tor compounds such as thromboxane A2 (TxA2) and sulfidopep-
tide leukotrienes (LTC4 and LTD4) [6, 7]. Thromboxane A2 is a
known vasoconstrictor whose release in response to endotoxin
in non-renal models of endotoxic injury has already been
demonstrated [8, 9]. The sulfidopeptide LTs have been shown
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to increase RVR in the intact animal [10] as well as in the
isolated perfused kidney [11]. They have also been shown to
contract isolated rat glomeruli [12] and, recently, these same
glomeruli have been shown to possess LT binding sites having
the biologic characteristics of true receptors [131. Of interest, in
numerous models of endotoxic shock, inhibition of arachidonic
acid metabolism, either at the level of cyclooxygenase with
aspirin or indomethacin, or through dietary modification, has
resulted in improved organ function and whole animal survival
[14—161.
In view of possible roles for TxA2 and LTs in endotox-
in—induced renal ischemia, we developed a model of E. Coli
endotoxin—induced acute renal failure in the rat, and measured
the renal hemodynamic changes as well as the renal cortical
generation rates of TxA2, prostaglandin E2 (POE2) and
prostaglandin 12 (P012), in response to endotoxin. Furthermore,
we selectively antagonized the effects of TxA2 and LTs in this
model of renal injury. Our results suggest an important role for
these products of arachidonic acid in sequentially mediating the
increase in RVR and the decrease in GFR during the first
seventy minutes following endotoxin administration. Results of
histologic studies suggest the release of these eicosanoids from
resident renal parenchymal cells rather than from infiltrating
cellular elements.
Methods
Physiologic studies
E. Co/i endotoxin (LPS) was obtained from List Biological
Laboratories (Campbell, California, USA). The preparation
used was National Reference Endotoxin (Lot EC-0113) as
prepared by Rudbach et a! [17]. Detailed description of the
chemical and biological properties of this endotoxin has been
published [17]. Concentrated solutions of LPS dissolved in
distilled water were stored at 4°C and aliquots used as needed.
UK-37248-Ol (dazoxiben) was obtained from Pfizers Pharma-
ceuticals (Pfizer Laboratories, New York, USA). FPL55712
was obtained from the Fisons Corp (Loughborough, U.K.).
Experiments were performed on adult male Munich—Wistar
rats (209 to 305 g) maintained on a standard rat pellet diet and
allowed free access to water. Each rat was anesthetized with
mactin (100 mg/kg, i.p.) and placed on a heated surgical table so
that body temperature was maintained at a baseline value of
37.0 to 37.5°C. Polyethelene catheters (PE 50) were placed in
the left femoral artery and femoral vein, The arterial catheter
474
Endotoxin—induced renal failure 475
was used for blood sampling and measurement of mean arterial
pressure (AP) with an electronic transducer (Model P23Db,
Statham Instruments Division, Gould Inc., Hato Rey, Puerto
Rico) connected to a direct writing recorder (Model 7754A,
Hewlett Packard Co., Elkhart, Indiana, USA). The venous
catheter was used for infusion of homologous rat plasma as
required to maintain euvolemia [18]. Following tracheostomy,
PE 50 catheters were introduced into both jugular veins for the
administration of a 7% inulin solution in 0.9% NaC1 at the rate
of 1.2 ml/hr, and for the administration of LPS, dazoxiben,
FPL-55712, or appropriate vehicles. The left kidney was ex-
posed via a subcostal incision and the left ureter was catheter-
ized with PE 10 tubing. An electromagnetic flow probe (ID =
1.5 mm) was placed on the left renal artery and connected to a
flow meter (Carolina Medical Electronics, Model 501), the
output of which was displayed on a second channel of the
Hewlett Packard recorder. To avoid contamination by the
laboratory environment, endotoxin was administered in steril-
ized Hamilton syringes. All other solutions were administered
in sterilized disposable plastic syringes.
—After a 45 to 60 minute period during which AP, RBF, and
urine flow were constant, two 15 mm clearance measurements
were performed and control values for AP and RBF were
recorded. Following these measurements, animals received
either vehicle injections or LPS, following which RBF was
monitored for 70 minutes, and clearance measurements per-
formed between 35 and 50 minutes and, in some animals,
between 60 and 70 minutes. The rats were divided into six
experimental groups as follows:
Group I—vehicle time controls (N = 10). These animals each
received an injection of 0.2 ml of 5% dextrose in water as a
vehicle control for LPS. In seven animals, the left kidney was
perfused with 0.9% NaCI at 50 minutes post-injection and then
processed for biochemical assays as described below. Three
animals were followed for 70 minutes. This group served as a
time control.
Group II—LPS alone (N = 18). The rats each received an
injection of 100 1Lg/kg of LPS in 0.2 ml of distilled water over
three minutes. Five animals were given 0.25 ml of 0.9% NaC1 10
minutes prior to LPS injection as vehicle controls for dazoxi-
ben—pre-treated rats (see Group IV). Five animals received a
continuous infusion of 0.45% NaCI starting 10 minutes before
and ending 30 minutes after LPS administration, at the rate
of 0.02 mI/mm, and served as vehicle controls for FPL-55712—
treated rats (see Group V). Since the response to LPS admin-
istration was indistinguishable among those animals which
received either of these two vehicle protocols and those which
received LPS alone, these animals were all considered as a
single group and their data pooled. In nine animals in this group,
biochemical assays were performed at 50 minutes post-LPS.
The remaining nine were followed for 70 minutes.
Group Ill—dazoxihen plus LPS-vehicle (N = 4). These rats
each received an injection of 0.2 ml of 5% dextrose in water
(LPS-vehicle) 10 minutes following administration of 10 mg/kg
of dazoxiben dissolved in 0.25 ml of 0.9% NaCI. In all animals
in this group, biochemical assays were performed 50 minutes
post-injection of 5% dextrose in water.
Group IV—dazoxiben plus LPS (N = 9). As in Group II,
these animals each received an injection of LPS 10 minutes
following intravenous administration of 10 mg/kg of dazoxiben
dissolved in 0.25 ml of 0.9% NaC1. Five animals underwent
biochemical assays at 50 minutes post-injection of the
endotoxin, while the remaining 4 animals were followed for 70
minutes post-LPS.
Group V—FPL-55712 plus LPS (N = 10). As in Group II,
these rats each received an injection of LPS in the presence of
a continuous intravenous infusion of FPL-55712 (500
xg/kg/min) dissolved in 0.45% NaCl started 10 mm prior to LPS
injection and maintained for 30 minutes post-injection. Four
animals underwent biochemical assays at 50 minutes post-LPS
and the remaining six were followed for 70 minutes.
Group VI—morphologic studies (N = 6). As in Group II,
these rats each received an injection of LPS (N =3), or vehicle(N = 3), followed, at 50 minutes post-injection, by perfusion
fixation of the kidneys and preparation for morphologic studies
as described below.
In Groups I, II, IV, and V, white blood cell counts were
obtained, using a Coulter counter, before and 50 minutes after
administration of either 5% dextrose in water or LPS.
Biochemical assays
In all animals in which biochemical assays were performed,
kidneys were perfused with cold saline until the venous effluent
was clear, excised, and the capsule gently removed. The kidney
was then bisected and the medulla and cortex rapidly separated
by fine dissection. Tissues were immediately moistened with
Krebs Ringer bicarbonate buffer (KRB) at pH 7.2 and 10 to 30
mg of tissues were finely, uniformly minced with a razor blade
and incubated in 2 ml KRB in a 25 ml flask on a shaker platform
in a 5% CO2 incubator at 37°C for 30 minutes. All supernatants
were immediately stored at —20°C for PGE2, 6 keto PGF1
and/or TxB2 analysis. It was not necessary to extract PGE2,
TxB2 or 6 keto PGF1. from tissues, since cyclooxygenase
metabolites accumulate in the medium rather than in the tissues
19].
PGE, TxB2, and 6 keto PGF1. assays. PGE2, TxB2 and 6 keto
PGF1, content in supernatant was determined by direct com-
petitive binding radioimmunoassays [201. Anti-PGE2 serum had
a 100% cross reactivity with PGE1 but only 2.7% with PGE2.
Therefore, our results can not differentiate PGE1 and PGE2.
However, since PGE2 was used as a standard we have ex-
pressed our results as PGE2 equivalents. Antisera to TxB2 did
not cross-react (0.04%) with other arachidonic acid metabolites
[21]. 6 keto PGF1a antisera had a cross reactivity as previously
described [221. 3H-PGE,, 3H-TXB2 and 3H 6 keto PGF1. were
purchased from New England Nuclear Corporation (Boston,
Massachusetts, USA). Values expressed for PGE2, TxB2 and 6
keto PGF1. represent the mean levels of duplicate determina-
tions. The assay sensitivities for TxB2, PGE2, and 6 keto PGF1,,
were 26 pg/mI, 30 to 40 pg/mI, and 30 to 40 pg/mI, respectively.
Intra-assay coefficients of variations were <2%.
Morphologic studies
For light and electron microscopy, kidneys from three
vehicle—treated and three endotoxin—treated animals were fixed
by perfusion at the measured arterial pressure with 1.25%
glutaraldelyde in 0.1 M cacodylate buffer (pH = 7.4) 50 minutes
following administration of either vehicle or LPS. The tissue
was then rinsed in buffer, postfixed in 1% osmium tetroxide,
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dehydrated, and embedded in epon 812. Thick sections (1 )
were stained with 0.5% toluidine blue in 1% aqueous borax.
Statistical analysis
Since A, RBF, and GFR were constant over the 45 to 60
minutes prior to administration of vehicle solution or LPS,
values for those parameters obtained immediately prior to the
administration of either substance were considered as pre-
injection controls. These values were compared to those ob-
tained at 50 and 70 minutes post-injection for all groups.
Physiologic parameters as well as biochemical measurements
were compared to each other using Wilcoxon's two—sample
statistic (Mann—Whitney). This analysis was applied for com-
parison of experimental to baseline values within individual
groups, as well as for inter-group comparisons. A P value of
less than 0.05 was considered necessary for statistical signifi-
cance. All values are reported as mean SEM.
Results
Physiologic studies
Whereas body temperature was stable at a mean value of 37.5
0.08°C in vehicle treated animals of Group 1, administration
of LPS resulted in a rise in body temperature by an average of
1.1°C from a baseline of 37.5 0.03°C to a mean peak value of
38.6 0.04°C (Group II) at 50 minutes. Neither dazoxiben nor
FPL-55712 prevented this hyperthermic response to endotoxin,
body temperature averaging 38.7 0.03°C and 38.6 0.05°C in
Groups IV and V, respectively, 70 minutes post-LPS. In
addition, LPS administration was associated with a significant
decrease in white blood cell count. In Group II animals, the
baseline value of 15.3 4.0 x io cells/mm3 fell to 4.2 1.0 X
l0 cells/mm3 (P < 0.05), a phenomenon not seen in vehicle
treated time controls (Group I). A similar fall was observed in
rats which received LPS in the presence of either dazoxiben
(Group IV) or FPL-55712 (Group V).
The administration of endotoxin resulted in hemoconcentra-
tion with a rise in hematocrit (Hct) from 47.2 0.6 to 51.0 0.8
vol% (Group H, P < 0.05). This effect was also seen in the
presence of dazoxiben (46.4 0.7 to 49.2 1.1, P < 0.05,
Group IV), but not in vehicle—injected time controls (46.2 0.6
to 46.4 0.9 vol%, Group I), animals receiving vehicle injec-
tion in the presence of dazoxiben (45.5 0.8 to 46.0 1.0
vol%, Group III), or animals receiving LPS in the presence of
the LT antagonist FPL-557l2 (46.4 1.1 to 47.7 1.1 vol%,
Group V).
Baseline AP was similar in all groups: 112 4, 116 3, 110
5, 115 3, and 108 3 mm Hg in Groups I, II, III, IV, and
V, respectively. Neither administration of vehicle solution
(Group I), LPS (Group II), dazoxiben plus vehicle (Group III),
dazoxiben plus LPS (Group IV), nor FPL-55712 plus LPS
(Group V) had any significant effect on AP over the ensuing 50
to 70 minutes of observation.
50 minutes after administration of vehicle, RBF was main-
tained at 7.1 0.3 mI/mm, a value not significantly different
from the baseline RBF of 7.0 0.2 mI/mm (Group 1). By
contrast, administration of LPS (Group II) resulted in a pro-
gressive fall in RBF, from a baseline of 6.9 0.2 mI/mm,
reaching a nadir of 3.8 0.4 mI/mm at 35 to 50 mm (P < 0.05
versus baseline and <0.001 versus Group I). This fall in RBF
was maintained 70 minutes post-LPS. The administration of
dazoxiben alone followed by vehicle injection (Group III) was
without significant effect on RBF, which changed from a control
value of 7.0 0.6 mI/mm to 6.7 0.7 mI/mm at 50 minutes. The
fall in RBF associated with endotoxin administration was
abrogated when LPS was administered in the presence of
dazoxiben (Group IV). In this group of animals, RBF fell from
7.2 0.3 to 6.3 0.4 mI/mm at 50 minutes post-LPS, a value
not significantly different from baseline (0.1 > P > 0.05), and
significantly greater (P < 0.001) than that obtained 50 minutes
post-LPS (Group 11). RBF was still maintained 70 minutes after
endotoxin administration in dazoxiben pre-treated animals. In
the presence of FPL-55712 (Group V), RBF fell from a mean
control value of 7.1 0.2 mI/mm to 4,8 0.8 mI/mm at 35
minutes following LPS injection (P < 0.005 versus pre-injection
control), but recovered to a value of 5.6 0.5 mI/mm at 50
minutes post-LPS. The latter value is still significantly reduced
as compared to pre-LPS levels (P < 0.05), but is significantly
greater (P < 0.01) than that obtained 50 minutes following
injection of LPS alone (Group II). The recovery of RBF in
FPL-557l2-treated animals continued until 70 minutes post-
LPS administration, at which time RBF averaged 5.9 0.5
mI/mm, a value not significantly different from pre-LPS control.
The time course of changes in RBF for Groups I, 11, IV, and V
is summarized in Figure I.
In parallel with its effect on RBF, LPS administration re-
sulted in a progressive fall in GFR in Group II animals, on
average from a baseline of 1.10 0.05 to 0.32 0.08 mI/mm (P
<0.001) between 35 and 50 minutes after its injection (Table 1).
This reduction in GFR was still present 70 minutes following
LPS (GFR = 0.27 0.07 mI/mm). No change in GFR was
observed, either at 50 or 70 minutes in vehicle—treated controls
(from 1.25 0.t)5 to 1.25 0.09 mI/mm, Group I) or when
vehicle injection was preceded by dazoxiben administration
(from 1.14 0.02 to 1.11 0.10 mI/mm, Group Ill). Dazoxiben
pre-treatment (Group IV) did not prevent the fall in GFR (from
8.0
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Fig. 1. Changes in RBF over the first 70 minutes following administra-
tion of LPS or vehicle in groups I, II, IV, and V. Symbols are: * P <
0.05 vs. Control; t P < 0.05 vs. LPS.
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Group
Control
GFR
GFR 50 mm
post-LPS or
vehicle
GFR 70 mm
post-LPS or
vehicle
1.21 0.03I (Vehicle) 1.25 0.05 1.25 0.09
II (LPS) 1.10 0.05 0.32 0.08k 0.27 0.07
IV (LPS +UK-37248) 1.18 0.05 0.67 008a,b 0.65 003a,b
V (LPS +FPL-55712) 1.05 0.10 0.46 0.15a 0.57 008a,b
1.18 0.05 to 0.67 0.08 mi/mm, P < 0.001) following LPS,
but the GFR value obtained between 35 and 50 minutes post-
LPS in dazoxiben pre-treated rats (0.67 0.08 mllmin) was
significantly greater (P < 0.005) than that obtained in animals
treated with LPS alone (0.32 0.08 mi/mm, Group II) and
remained higher 70 minutes following endotoxin administration.
The administration of FPL-55712 to LPS-treated animals in
Group V failed to ameliorate the fall in GFR seen at 50 minutes
post-LPS (GFR fell from 1.05 0.10 ml/min to 0.46 0.15
mi/mm, P < 0.005). The difference between the values of GFR
obtained 50 minutes following LPS alone (0.32 0.08 mllmin,
Group II) and that obtained following LPS in the presence of
FPL-557l2 (0.46 0.15 mi/mm, Group V) did not attain
statistical significance. At 70 minutes, however, GFR had
recovered to 0.57 0.08 ml/min in FPL-55712 treated animals
(Group V), a value significantly different from that obtained for
rats receiving LPS alone (0.27 0.07 ml/min, P < 0.025). The
changes in GFR following LPS administration for the Groups I,
II, IV, and V are summarized in Table 1.
Biochemical assays
Baseline renal cortical generation rates of TxB2, PGE2 and 6
keto PGF1, as measured 50 minutes following administration
of vehicle in Group I animals, averaged 35 9, 466 107, and
94 3 pg/mg, respectively. Administration of LPS (Group II)
resulted in a significant increase in all three products with
generation rates of 106 12 pg/mg for TxB2 (P <0.005), 1075
108 pg/mg for PGE2 (P < 0.025), and 221 41 pg/mg for 6
keto PGF1 (P <0.05) (Fig. 2).
Dazoxiben administration alone (Group III) had no significant
effect on TxB2 (29 3 pg/mg) or PGE2 (628 51 pg/mg)
generation as compared to time controls, but did result in an
increase in baseline 6 keto PGF12 levels to 322 166 pg/mg (P
< 0.05). When dazoxiben pre-treated animals were given
endotoxin (Group IV), TxB2 generation was inhibited to 29 3
pg/mg (not significantly different from Group I, but significantly
less than Group II, P < 0.005). LPS-induced increases in PGE2
and 6 keto PGFia generation, however, were not affected by
dazoxiben pre-treatment, values averaging 837 62 pg/mg for
PGE2 (P < 0.005 versus Group I and >0.05 versus Group II)
and 179 5 pg/mg for 6 keto PGF1 (P < 0.05 versus Group I
and >0.05 versus Group II). In rats receiving LPS in the
presence of FPL-55712, renal cortical generation rates of TxB2
were not different from those receiving LPS alone (97 17
pg/mg), and were significantly greater than baseline levels
observed in Group I (P < 0.005). Figure 2 summarizes the
prostanoid generation rates for Groups I, II, and IV.
Morphologic studies
Light microscopic examination of kidneys from vehicle—
treated and endotoxin—treated animals failed to reveal any
differences beween the two groups and was consistent with the
appearance of normal rat kidney. In particular, there was no
increase in glomerular cellularity and platelet adhesion to
vascular endothelium was not noted.
Discussion
Administration of LPS was associated with its well known
capacity to increase body temperature and decrease circulating
white blood cell count [23]. Neither of these effects were
abolished by dazoxiben or FPL-55712. The hemoconcentration
which followed LPS administration, while being unaffected by
TxA2 synthetase inhibition, was abolished by FPL-55712. In
previous studies, this same compound was capable of abolish-
ing the rise in hematocrit seen following exogenous administra-
tion of leukotriene C4 [10], an effect shown to be secondary to
LT-induced plasma volume loss, likely resulting from its
vasopermeability—enhancing effect [24]. Since the rise in hem-
atocrit following LPS administration is probably secondary to
Table 1. GFR 50 and 70 minutes after LPS (100 tg/kg) or vehicle
Values are mean SEM.
a p < 0.05 vs. Control
b P < 0.05 vs. Group II
Tx B2
*
I I
PGE2
*
100
50
0—
500
1000
0)
E
C)0.
500
0
300
200
100
0
Vehicle LPS LPS+UK—37248
Fig. 2. Changes in renal cortical generation rates of TxB2, PGE2, and 6
keto PGF1 50 mm after vehicle (Group I), LPS (Group II), and LPS in
the presence of UK-37248 (Group IV). Symbols are: * P < 0.05 vs.
Vehicle; P < 0.05 vs. LPS.
6 Keto PGF1,,
*I
*
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plasma volume loss [25], the capacity of FPL-55712 to prevent
such losses suggests a role for endogenously produced LTs in
mediating this effect. Despite prevention of hemoconcentration,
FPL-55712 failed to abrogate the early fall in RBF and GFR
seen at 50 minutes following LPS administration (Figure 1 and
Table 1). Therefore, in this model of renal injury, factors other
than those consequent to a loss of plasma volume play a role in
the endotoxin—induced changes in renal hemodynamics.
Despite constancy of AP, RBF fell progressively starting 15
to 20 mm after LPS administration reaching a nadir at 45 to 50
mm (Fig, 1), thereby implicating an increase in renal vascular
resistance as an underlying mechanism. (RVR increased from
17 2 to 31 3 mm Hg/mI-mm, P < 0.01). This finding in the
rat is in contrast to most studies of renal function during
endotoxemia performed in the dog [3, 251 in which a fall in
AP was almost always observed whether LPS was administered
as a single bolus or by continuous infusion [26]. It is, however,
consistent with the findings of Keeler [2] in the rat in which
continuous infusion of E. Coli endotoxin resulted in an increase
in RVR despite maintenance of AP. The rat has often been
regarded as relatively insensitive to the systemic cardiovascular
effects of endotoxin, thereby allowing for more rigorous evalu-
ation of its renal actions. In the present study, the increase in
RVR was accompanied by an increase in renal cortical gener-
ation rates of TxB2, PGE2, and 6 keto PGF1 (Fig. 2). These
findings in kidney tissue are consistent with numerous obser-
vations in endotoxin—treated animals reported by others in
which increases in both vasoconstrictor (TxA2) and vasodilator
(PGE2 and PGI2) products of arachidonic acid have been
demonstrated in a variety of tissues [8, 14. 27]. Endotoxin is a
potent stimulus of white blood cells in vitro leading to the
release of arachidonic acid and its cyclooxygenase and
lipoxygenase metabolites [6, 71. Since TxA2, a potent vasocon-
strictor, has been implicated in the pulmonary vasoconstriction
following endotoxin in goats [91 and its inhibition shown to
result in beneficial effects in various models of endotoxic injury
[28—30], we attempted to selectively prevent its synthesis in this
model of endotoxin—induced renal ischemia. Dazoxiben was
shown to selectively inhibit the synthesis of TxA2 without
apparent shunting of arachidonate into increased PGE2 or PGI2
synthesis (Fig. 2). This inhibition of TxA2 synthesis was asso-
ciated with prevention of the endotoxin—associated fall in RBF
(Fig. 1), thereby assigning a major role for this eicosanoid in the
endotoxin—induced increase in RVR. (RVR was unchanged; 16
3 to 18 4 mm Hg/mI-mm, P > 0.05). In contrast to
dazoxiben pre-treatment, administration of the LT antagonist
FPL-55712 in a dose previously shown to totally block the
effects of exogeneously administered LTC4 in the same strain of
rats [10], partially prevented the fall in RBF at 35 to 40 mm
following endotoxin (Fig. I). (RVR increased from 15 2 to 23
3 mm Hg/mI-mm, P < 0.05). However, antagonism of
endogenous LTs, in the presence of FPL-55712, resulted in
total recovery of RBF 70 minutes post-endotoxin, an effect not
seen in its absence (Fig. 1). That the salutary effect of
FPL-55712 was not due to inhibition of TxA2, is shown by the
lack of inhibition of the endotoxin—induced increase in TxA2
generation in Group V animals.
The administration of endotoxin was associated with a dra-
matic reduction in GFR, measured as inulin clearance, between
35 and 50 minutes as well as between 60 and 70 minutes after its
administration. The fall in GFR was not due solely to the fall in
renal plasma flow since filtration fraction fell from 0.31 to 0.17
(at 50 minutes) and 0.14 (at 70 minutes). Factors other than
renal hypoperfusion were therefore involved in mediating the
fall in GFR in this model of acute renal injury. Of interest is the
fact that despite prevention of the fall in RBF in dazoxiben
treated animals, GFR, though significantly ameliorated, was not
totally preserved. Furthermore, the LT antagonist FPL-55712,
while resulting in significant recovery of RBF at 70 minutes,
was also associated with attenuation of the fall in GFR at this
time, but not its abrogation (Table 1). Of note, in the presence
of either dazoxiben or FPL-55712, filtration fraction remained
depressed at 70 minutes post-endotoxin, averaging 0.21 and
0.18, respectively. Antagonism of TxA2 and vasoconstrictor
LTs, therefore, had greater protective effect on RBF than on
GFR, though both were significantly improved relative to
values in untreated animals. These observations suggest that, in
addition to the fall in nephron perfusion caused, at least in part,
by the presence of vasoconstrictor eicosanoids, other determi-
nants of GFR must be depressed. Possible mechanisms include
a fall in transcapillary hydraulic pressure related to afferent
arteriolar constriction as well as a fall in the glomerular ultra-
filtration coefficient. The latter may result from the intrarenal
release of angiotensin II, a well known response to renal
hypoperfusion.
In view of the above findings implicating the vasoconstrictor
properties of TxA2 and sulfidopeptide LTs in endotoxin—in-
duced renal ischemia, the issue of the source of these com-
pounds during this model of injury becomes relevant. When
kidneys were fixed perfused at 50 minutes post-endotoxin, (the
time of maximal fall in RBF) using a method of perfusion
fixation previously shown to perserve cellular elements adher-
ent to the endothelial surface [31], a remarkable absence of
platelet or other cellular infiltration was noted. Since sections of
cortical tissue used for biochemical assays were also free of
platelet or other cellular infiltrates, it seems possible that the
major source of the increased levels of TxA2, PGE2, and PGI2
in this form of renal injury is from indigenous renal parenchy-
mal cells. In this regard, mesangial cells of macrophage—mono-
cyte origin seem the most likely candidates to respond to the
endotoxic stimulus [32—34]. Isolated glomeruli from kidneys
subjected to antiglomerular basement membrane—antibody—
induced injury are known to produce increased amounts of
TxA2 and other eicosanoids [321. Furthermore, recent evidence
has suggested that the isolated perfused rat kidney is capable of
synthesizing sulfidopeptide leukotrienes when stimulated with
the calcium ionophore A23 187 [351 and the enzymatic pathway
leading to the synthesis of leukotrienes has been identified in
renal tissue [35—37]. Our studies raise the possibility that these
products play a role in mediating renal vasoconstriction in this
model of acute renal failure.
In summary, the present experiments in the rat demonstrate
the capacity of E. Coli endotoxin to induce an acute increase in
RVR in the absence of systemic hypotension, and to decrease
RBF, GFR, and filtration fraction. As in other organ beds,
endotoxin seems to stimulate the synthesis of TxA2 and other
cyclooxygenase products in the renal cortex, and this vasocon-
strictor appears to play a major role in the reduced renal
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perfusion and filtration rate seen during the early phase (35 to 50
minutes) of endotoxemic injury. In addition, evidence is pre-
sented to suggest that endogenously produced sulfidopeptide
leukotrienes, previously shown to be potent constrictors of the
renal vasculature, also play a role in perpetuating renal
vasconstriction at 60 to 70 minutes following endotoxin admin-
istration. While our methodology cannot totally exclude the
possibility of extrarenal cellular or platelet elements as sources
for the increased release of these eicosanoids, histologic exam-
ination failed to demonstrate the presence of such elements in
the kidney at the height of the renal injury, thereby suggesting
an intrinsic renal source.
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